Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

Autor: Mark N. Polizzotto, Jacqueline Nordwall, Abdel G. Babiker, Andrew Phillips, David M. Vock, Nnakelu Eriobu, Vivian Kwaghe, Roger Paredes, Lourdes Mateu, Srikanth Ramachandruni, Rajeev Narang, Mamta K. Jain, Susana M. Lazarte, Jason V. Baker, Anne E.P. Frosch, Garyfallia Poulakou, Konstantinos N. Syrigos, Gretchen S. Arnoczy, Natalie A. McBride, Philip A. Robinson, Farjad Sarafian, Sanjay Bhagani, Hassan S. Taha, Thomas Benfield, Sean T.H. Liu, Anastasia Antoniadou, Jens Ulrik Stæhr Jensen, Ioannis Kalomenidis, Adityo Susilo, Prasetyo Hariadi, Tomas O. Jensen MD, Jose Luis Morales-Rull, Marie Helleberg, Sreenath Meegada, Isik S. Johansen, Daniel Canario, Eduardo Fernández-Cruz, Simeon Metallidis, Amish Shah, Aki Sakurai, Nikolaos G. Koulouris, Robin Trotman, Amy C. Weintrob, Daria Podlekareva, Usman Hadi, Kathryn M. Lloyd, Birgit Thorup Røge, Sho Saito, Kelly Sweerus, Jakob J. Malin, Christoph Lübbert, Jose Muñoz, Matthew J. Cummings, Marcelo H. Losso, Dan Turner, Kathryn Shaw-Saliba, Robin Dewar, Helene Highbarger, Perrine Lallemand, Tauseef Rehman, Norman Gerry, Dona Arlinda, Christina C. Chang, Birgit Grund, Michael R. Holbrook, Horace P. Holley, Fleur Hudson, Laura A. McNay, Daniel D. Murray, Sarah L. Pett, Megan Shaughnessy, Mary C. Smolskis, Giota Touloumi, Mary E. Wright, Mittie K. Doyle, Sharon Popik, Christine Hall, Roshan Ramanathan, Huyen Cao, Elsa Mondou, Todd Willis, Joseph V. Thakuria, Leman Yel, Elizabeth Higgs, Virginia L. Kan, Jens D. Lundgren, James D. Neaton, H. Clifford Lane

Publikováno v: Lancet (London, England)

Background Passive immunotherapy using hyperimmune intravenous immunoglobulin (hIVIG) to SARS-CoV-2, derived from recovered donors, is a potential rapidly available, specific therapy for an outbreak infection such as SARS-CoV-2. Findings from randomi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3fa915184eaa7554ec475c89515acde
https://doi.org/10.1016/s0140-6736(22)00101-5

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

Autor: Sabue, Mulangu, Lori E, Dodd, Richard T, Davey, Olivier, Tshiani Mbaya, Michael, Proschan, Daniel, Mukadi, Mariano, Lusakibanza Manzo, Didier, Nzolo, Antoine, Tshomba Oloma, Augustin, Ibanda, Rosine, Ali, Sinaré, Coulibaly, Adam C, Levine, Rebecca, Grais, Janet, Diaz, H Clifford, Lane, Jean-Jacques, Muyembe-Tamfum, Billy, Sivahera, Modet, Camara, Richard, Kojan, Robert, Walker, Bonnie, Dighero-Kemp, Huyen, Cao, Philippe, Mukumbayi, Placide, Mbala-Kingebeni, Steve, Ahuka, Sarah, Albert, Tyler, Bonnett, Ian, Crozier, Michael, Duvenhage, Calvin, Proffitt, Marc, Teitelbaum, Thomas, Moench, Jamila, Aboulhab, Kevin, Barrett, Kelly, Cahill, Katherine, Cone, Risa, Eckes, Lisa, Hensley, Betsey, Herpin, Elizabeth, Higgs, Julie, Ledgerwood, Jerome, Pierson, Mary, Smolskis, Ydrissa, Sow, John, Tierney, Sumathi, Sivapalasingam, Wendy, Holman, Nikki, Gettinger, David, Vallée, Jacqueline, Nordwall, Marie Claire, Kolie

Publikováno v: The New England journal of medicine. 381(24)

Although several experimental therapeutics for Ebola virus disease (EVD) have been developed, the safety and efficacy of the most promising therapies need to be assessed in the context of a randomized, controlled trial.We conducted a trial of four in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5163ecc384f84ed14501bcbea1cb293d
https://pubmed.ncbi.nlm.nih.gov/31774948